Evotec and Takeda enter into multi-year gene therapy research alliance
Evotec SE announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programmes.
Under the alliance, Evotec will support multiple Takeda programmes targeting conditions aligned with Takeda’s four core therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology. The alliance leverages Evotec’s growing gene therapy capabilities as well as Evotec’s broader drug discovery platform.
Dr Steven Hitchcock, Global Head of Research for Takeda, said: “We are excited to be broadening and expanding our discovery efforts with the Evotec team. Gene therapy is a growing therapeutic approach in our portfolio and this alliance with Evotec will help us further accelerate our delivery of transformative therapies for patients, particularly those with rare diseases.”
Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “We’re pleased to expand the scope of our collaboration with Takeda into gene therapy by establishing an alliance with Takeda. This new alliance demonstrates the value of our multimodality platform with innovative technologies and best-in-class execution for addressing the most urgent requirements of our partners. Relationships like this will transform industry’s approach to drug discovery and development to ultimately find new therapies.”
No financial details of the agreement were disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Last viewed contents
Modern humans developed a more effective protection against oxidative stress - Neanderthal variant of the protein glutathione reductase increases risk for inflammatory bowel disease and vascular disease
UC San Diego biologists discover genes that repair nerves after injury
Fantastic muscle proteins and where to find them - “This is going to be unexpected even for myosin researchers”
GxP Consulting Announces New Expansion Strategy into US and UK Markets
BioGaia signs distribution and license agreements with partner in Japan
Mechanism for DNA Invasion of Adenoviral Covid-19 Vaccines Discovered - Premature release of DNA activates anti-viral alarm systems
Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer - First targeted biological therapy to show survival benefit in stomach cancer
Cancer Treatment with Built-in Light - Deep photodynamic therapy: photosensitizer irradiates itself
Silence Therapeutics Forms Scientific Advisory Board
